Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

BACKGROUND: Despite the success of immune checkpoint inhibitors against PD-L1 in the clinic, only a fraction of patients benefit from such therapy. A theoretical strategy to increase efficacy would be to arm such antibodies with Fc-mediated effector mechanisms. However, these effector mechanisms are...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamdan, Firas, Ylösmäki, Erkko, Chiaro, Jacopo, Giannoula, Yvonne, Long, Maeve, Fusciello, Manlio, Feola, Sara, Martins, Beatriz, Feodoroff, Michaela, Antignani, Gabriella, Russo, Salvatore, Kari, Otto, Lee, Moon Hee, Järvinen, Petrus, Nisen, Harry, Kreutzman, Anna, Leusen, Jeanette, Mustjoki, Satu, McWilliams, Thomas G, Grönholm, Mikaela, Cerullo, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351494/
https://www.ncbi.nlm.nih.gov/pubmed/34362830
http://dx.doi.org/10.1136/jitc-2021-003000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351494/
https://www.ncbi.nlm.nih.gov/pubmed/34362830
http://dx.doi.org/10.1136/jitc-2021-003000

Ejemplares similares